Literature DB >> 15929681

The development and validation of the Norfolk QOL-DN, a new measure of patients' perception of the effects of diabetes and diabetic neuropathy.

Etta J Vinik1, Risa P Hayes, Alan Oglesby, Edward Bastyr, Patricia Barlow, Stephanie L Ford-Molvik, Aaron I Vinik.   

Abstract

BACKGROUND: This study was designed to develop and validate a patient-reported outcomes measure, sensitive to the different features of diabetic neuropathy (DN)-small fiber, large fiber, and autonomic nerve function.
METHODS: The review of 1,000 structured patient interviews guided the development of 28 items pertaining specifically to the symptoms and impact of large fiber, small fiber, and autonomic nerve function. These items, in addition to 14 generic health status items and five general information items formed the 47-item Norfolk Quality of Life Questionnaire-Diabetic Neuropathy (QOL-DN). Items were grouped according to small fiber, large fiber, and autonomic nerve function, symptoms, and activities of daily living (ADL). Scores in individual domains were aggregated to provide a total score. Item groupings were tested for their ability to distinguish between the effects of specific nerve fiber deficits in 262 subjects-81 healthy controls (C), 86 controls with diabetes (DC), and 95 patients with DN-using one-way analysis of variance (ANOVA). Internal consistency was estimated using Cronbach's alpha coefficient. Test-retest reliability over a 4-6-week period was estimated by intra-class correlation coefficients and ANOVA on data of a subset of patients and controls.
RESULTS: Differences between DN subjects and both DC and C subjects were significant (P < 0.05) for all item groupings. Total quality of life (QOL) scores correlated with total neuropathy scores. The ADL, total QOL, and autonomic scores were greater in DC than C subjects (P < 0.05). Intra-class correlation coefficients were > 0.9 for most domains. Internal consistency of the fiberspecific domains using Cronbach's alpha was > 0.6 and up to 0.8.
CONCLUSIONS: The fiber-specific domains of the QOL-DN demonstrated acceptable reliability and ability to discriminate between subjects with and without neuropathy. Not surprisingly, the DN group scored significantly (P < 0.05) higher than either of the two control groups (i.e., greater impairment). The positive scores for the DC group in the ADL and autonomic domains suggest that diabetes per se impacts these aspects of QOL.

Entities:  

Mesh:

Year:  2005        PMID: 15929681     DOI: 10.1089/dia.2005.7.497

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  57 in total

1.  The health-related utility and health-related quality of life of hospital-treated subjects with type 1 or type 2 diabetes with particular reference to differing severity of peripheral neuropathy.

Authors:  C J Currie; C D Poole; A Woehl; C Ll Morgan; S Cawley; M D Rousculp; M T Covington; J R Peters
Journal:  Diabetologia       Date:  2006-08-30       Impact factor: 10.122

Review 2.  Diabetic neuropathy in older adults.

Authors:  Aaron I Vinik; Elsa S Strotmeyer; Abhijeet A Nakave; Chhaya V Patel
Journal:  Clin Geriatr Med       Date:  2008-08       Impact factor: 3.076

3.  Quality of life and objective measures of diabetic neuropathy in a prospective placebo-controlled trial of ruboxistaurin and topiramate.

Authors:  Amanda Boyd; Carolina Casselini; Etta Vinik; Aaron Vinik
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

4.  Development and Validation of the Norfolk Quality of Life Fatigue Tool (QOL-F): A New Measure of Perception of Fatigue.

Authors:  Etta J Vinik; Aaron I Vinik; Serina A Neumann; Rajan Lamichhane; Steven Morrison; Sheri R Colberg; Ying-Chuen Lai; James Paulson; Richard Handel; Carolina Casellini; Kim Hodges; Joshua Edwards; Henri K Parson
Journal:  J Am Med Dir Assoc       Date:  2019-12-16       Impact factor: 4.669

5.  Activity for Diabetic Polyneuropathy (ADAPT): Study Design and Protocol for a 2-Site Randomized Controlled Trial.

Authors:  Patricia M Kluding; J Robinson Singleton; Mamatha Pasnoor; Mazen M Dimachkie; Richard J Barohn; A Gordon Smith; Robin L Marcus
Journal:  Phys Ther       Date:  2017-01-01

6.  Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial.

Authors:  Teresa Coelho; Luis F Maia; Ana Martins da Silva; Marcia Waddington Cruz; Violaine Planté-Bordeneuve; Pierre Lozeron; Ole B Suhr; Josep M Campistol; Isabel Maria Conceição; Hartmut H-J Schmidt; Pedro Trigo; Jeffery W Kelly; Richard Labaudinière; Jason Chan; Jeff Packman; Amy Wilson; Donna R Grogan
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

7.  Detecting subtle fingertip sensory and motor dysfunction in adults with type II diabetes.

Authors:  Stacey L Gorniak; Aisha Khan; Nereyda Ochoa; Morali D Sharma; Cecile L Phan
Journal:  Exp Brain Res       Date:  2014-01-28       Impact factor: 1.972

Review 8.  Content validity of symptom-based measures for diabetic, chemotherapy, and HIV peripheral neuropathy.

Authors:  Jennifer S Gewandter; Laurie Burke; Guido Cavaletti; Robert H Dworkin; Christopher Gibbons; Tony D Gover; David N Herrmann; Justin C Mcarthur; Michael P McDermott; Bob A Rappaport; Bryce B Reeve; James W Russell; A Gordon Smith; Shannon M Smith; Dennis C Turk; Aaron I Vinik; Roy Freeman
Journal:  Muscle Nerve       Date:  2016-12-23       Impact factor: 3.217

9.  Utilization of nerve conduction studies for the diagnosis of polyneuropathy in patients with diabetes: a retrospective analysis of a large patient series.

Authors:  Xuan Kong; Eugene A Lesser; Frisso A Potts; Shai N Gozani
Journal:  J Diabetes Sci Technol       Date:  2008-03

10.  German-translated Norfolk quality of life (QOL-DN) identifies the same factors as the English version of the tool and discriminates different levels of neuropathy severity.

Authors:  Etta J Vinik; James F Paulson; Stephanie L Ford-Molvik; Aaron I Vinik
Journal:  J Diabetes Sci Technol       Date:  2008-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.